Physician profile
Taylor Barrett
NPI 1861965493
$14,632.15
in general payments reported to CMS, 2019-2025
26 companies · $3,138 in 2025
The $3,138 reported for 2025 was more than what 97% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,856 · 2022: $2,805 · 2023: $3,044 · 2024: $3,789 · 2025: $3,138.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,971.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,970.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $2,238.94 | 2021-2025 | Qelbree, Qelbree |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $2,150.03 | 2021-2025 | Caplyta |
| Abbvie INC. | $1,460.12 | 2021-2025 | |
| Alkermes, INC. | $1,442.28 | 2021-2025 | Aristada, Lybalvi |
| Otsuka America Pharmaceutical, INC. | $1,252.32 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Tris Pharma INC | $1,082.72 | 2021-2025 | Dyanavel Xr, Onyda Xr |
| Ironshore Pharmaceuticals INC. | $906.77 | 2021-2024 | Jornay Pm |
| Takeda Pharmaceuticals U.S.A., INC. | $767.07 | 2021-2025 | Trintellix |
| Corium, LLC | $747.53 | 2022-2025 | Azstarys |
| Axsome Therapeutics, INC. | $621.90 | 2022-2025 | Auvelity, Sunosi |
| Lundbeck LLC | $561.32 | 2021-2025 | Rexulti, Abilify Maintena |
| Janssen Pharmaceuticals, INC | $207.93 | 2021-2025 | Spravato |
| Idorsia Pharmaceuticals US INC | $164.23 | 2022-2023 | Quviviq |
| Collegium Pharmaceutical, INC. | $160.01 | 2025 | Jornay Pm |
| Almatica Pharma LLC | $151.29 | 2022-2024 | Loreev Xr, Sertraline Hcl |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neos Therapeutics, LP | $124.81 | 2022-2024 | Adzenys Xr-Odt, Cotempla Xr-Odt |
| E.R. Squibb & Sons, L.L.C. | $119.67 | 2024-2025 | Cobenfy |
| Teva Pharmaceuticals USA, INC. | $95.88 | 2021-2025 | Austedo, Austedo Xr |
| Vertical Pharmaceuticals, LLC | $83.77 | 2024 | Relexxii |
| Adlon Therapeutics L.P. | $68.50 | 2021 | |
| Noven Therapeutics, LLC | $65.90 | 2024 | Secuado, Xelstrym |
| Eisai INC. | $65.28 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $39.24 | 2021 | |
| Noven Pharmaceuticals, INC. | $19.95 | 2024 | Xelstrym |
| Vanda Pharmaceuticals INC. | $17.60 | 2025 | Fanapt |
| Jazz Pharmaceuticals INC. | $17.09 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Taylor Barrett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.